Background: Accurate staging is crucial for the proper management of patients with
nonsmall cell lung cancer, especially for choosing the best treatment strategy. Different …

PURPOSE: To retrospectively evaluate the clinical impact of FDG PET–CT on the
management pathway of patients with lung cancer. PATIENTS AND METHODS: One …

Objective To investigate whether differences in thoracic tumour staging between 18 F-FDG
PET/CT and PET/MR imaging lead to different therapeutic decisions in Non-Small Cell Lung …

Aim: Currently, the German and Austrian S3 guidelines on the evaluation and treatment of
lung cancer are about to be published whereas the American Colleague of Chest …

OBJECTIVE. We determined the prognostic value of 18F-fluorodeoxyglucose (FDG) positron
emission tomography (PET) for patients with treated lung cancer. MATERIALS AND …

Lung cancer is the leading cause of cancer-related mortality in the United States, and
accurate staging plays a vital role in determining prognosis and treatment. The recently …

Objectives To compare the diagnostic performance of 18 F-FDG PET/MRI and 18 F-FDG
PET/CT for primary and locoregional lymph node staging in non-small cell lung cancer …

An estimated 180,000 new cases of lung cancer will be diag nosed in the US this year, and
lung cancer accounts for approximately 25% of all cancer deaths. Most lung cancers are …

The primary clinical application of FDG-PET is in the evaluation of patients with lung cancer
and includes diagnosis, staging and restaging of non-small cell lung cancer. PET has a very …

An estimated 180,000 new cases of lung cancer will be diagnosed in the United States this
year, and lung cancer accounts for approximately 25% of all cancer deaths. The overall 5 …